Causal modeling using network ensemble simulations of genetic and gene expression data predicts genes involved in rheumatoid arthritis
| Autor: | John P. Carulli, Heming Xing, Karl Runge, Tanya Cashorali, Jadwiga Bienkowska, Bruce Church, David DeCaprio, Robert E. Miller, Ronenn Roubenoff, Iya Khalil, Paul D. McDonagh |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
musculoskeletal diseases
Immunoconjugates In silico Immunology Regulator Arthritis Gene Expression Biology Bioinformatics Abatacept Arthritis Rheumatoid Cellular and Molecular Neuroscience Gene expression Sphingosine N-Acyltransferase Genetics medicine Humans Computer Simulation Molecular Biology lcsh:QH301-705.5 Rheumatology/Rheumatoid Arthritis Ecology Evolution Behavior and Systematics Genetics and Genomics/Medical Genetics Computational Biology/Systems Biology Ecology Tumor Necrosis Factor-alpha Gene Expression Profiling Interleukins Genetics and Genomics/Gene Therapy Computational Biology Genetics and Genomics Genetics and Genomics/Gene Expression Genetics and Genomics/Bioinformatics medicine.disease Gene expression profiling Genetics and Genomics/Gene Function Computational Theory and Mathematics lcsh:Biology (General) Modeling and Simulation Rheumatoid arthritis Antirheumatic Agents Tumor necrosis factor alpha Genetics and Genomics/Gene Discovery medicine.drug Research Article |
| Zdroj: | PLoS Computational Biology PLoS Computational Biology, Vol 7, Iss 3, p e1001105 (2011) |
| ISSN: | 1553-7358 |
| Popis: | Tumor necrosis factor α (TNF-α) is a key regulator of inflammation and rheumatoid arthritis (RA). TNF-α blocker therapies can be very effective for a substantial number of patients, but fail to work in one third of patients who show no or minimal response. It is therefore necessary to discover new molecular intervention points involved in TNF-α blocker treatment of rheumatoid arthritis patients. We describe a data analysis strategy for predicting gene expression measures that are critical for rheumatoid arthritis using a combination of comprehensive genotyping, whole blood gene expression profiles and the component clinical measures of the arthritis Disease Activity Score 28 (DAS28) score. Two separate network ensembles, each comprised of 1024 networks, were built from molecular measures from subjects before and 14 weeks after treatment with TNF-α blocker. The network ensemble built from pre-treated data captures TNF-α dependent mechanistic information, while the ensemble built from data collected under TNF-α blocker treatment captures TNF-α independent mechanisms. In silico simulations of targeted, personalized perturbations of gene expression measures from both network ensembles identify transcripts in three broad categories. Firstly, 22 transcripts are identified to have new roles in modulating the DAS28 score; secondly, there are 6 transcripts that could be alternative targets to TNF-α blocker therapies, including CD86 - a component of the signaling axis targeted by Abatacept (CTLA4-Ig), and finally, 59 transcripts that are predicted to modulate the count of tender or swollen joints but not sufficiently enough to have a significant impact on DAS28. Author Summary The collection and analysis of clinical data has played a key role in providing insights into the diagnosis, prognosis and treatment of disease. However, it is imperative that molecular and genetic data also be collected and integrated into the creation of network models, which capture underlying mechanisms of disease and can be interrogated to elucidate previously unknown biology. Bringing data from the clinic to the bench completes the cycle of translational research, which we demonstrate with this work. We built disease models from genetics, whole blood gene expression profiles and the component clinical measures of rheumatoid arthritis using a data-driven approach that leverages supercomputing. Genetic factors can be utilized as a source of perturbation to the system such that causal connections between genetics, molecular entities and clinical outcomes can be inferred. The existing TNF-α blocker treatments for rheumatoid arthritis are only effective for approximately 2/3 of the affected population. We identified novel therapeutic intervention points that may lead to the development of alternatives to TNF-α blocker treatments. We believe this approach will provide improved drug discovery programs, new insights into disease progression, increased drug efficacy and novel biomarkers for chronic and complex diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|